FDA approves label change for Depo-Provera, adding brain tumor warning

The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns ...
BioPharma Dive

FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...
BioSpace

Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...

2 headwinds facing Pfizer stock going into 2026

There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.
newscase

Regulatory Headwinds Rattle BioNTech and Vaccine Sector

Shares of BioNTech, the German vaccine innovator, came under significant pressure on a pivotal Tuesday. The sell-off, which also dragged down sector peers in ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.

Keep your expectations in check.

Down 50%, Should You Buy the Dip on Pfizer?

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Will Pfizer’s YaoPharma deal deliver a powerful new oral obesity pill?

Pfizer bets on YaoPharma’s oral GLP-1 pill YP05002 after past failures, aiming to rejoin the booming $150B obesity-drug market.